Incidence of Adverse Effects and Discontinuation Rate between Patients Receiving 250 Micrograms and 500 Micrograms of Roflumilast: A Comparative Study

BACKGROUND: Roflumilast is the only approved oral phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease (COPD) in patients with chronic bronchitis and a history of frequent exacerbations. The purpose of this study was to examine the incidence of adverse effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Joo, Hyonsoo, Han, Deokjae, Lee, Jae Ha, Rhee, Chin Kook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Tuberculosis and Respiratory Diseases 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148098/
https://www.ncbi.nlm.nih.gov/pubmed/29926552
http://dx.doi.org/10.4046/trd.2018.0015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148098/
https://www.ncbi.nlm.nih.gov/pubmed/29926552
http://dx.doi.org/10.4046/trd.2018.0015

Ejemplares similares